How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Veterinary Insulin Syringes Market
- By Product Type: Insulin Syringes with Fixed Needle, Insulin Syringes with Detachable Needle, Prefilled Insulin Syringes, Disposable Insulin Syringes
- By Needle Gauge: 28 Gauge, 29 Gauge, 30 Gauge, 31 Gauge
- By Needle Length: 6 mm, 8 mm, 12.7 mm, 16 mm
- By End User: Veterinary Clinics, Animal Hospitals, Research Laboratories, Farm Animal Care Facilities
- By Packaging Type: Single Pack, Multi-Pack, Bulk Packaging
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Insulin Syringes with Fixed Needle leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 293 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.175 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.183 →
Full report · locked preview
Everything inside the Veterinary Insulin Syringes Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Product Type 4
Needle Gauge 4
Needle Length 4
End User 4
Packaging Type 3
Companies profiled
Becton
Dickinson and Company (BD)
Terumo Corporation
Nipro Corporation
Eli Lilly and Company
B. Braun Melsungen AG
Ypsomed AG
Owen Mumford Ltd
Nipro Medical Corporation
Sahajanand Medical Technologies Pvt. Ltd.
Jiangsu Yuyue Medical Equipment & Supply Co. Ltd.
HMD Medical Products
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Nipro Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →B. Braun Melsungen AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Ypsomed AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Owen Mumford Ltd
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Nipro Medical Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sahajanand Medical Technologies Pvt. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Jiangsu Yuyue Medical Equipment & Supply Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →HMD Medical Products
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Unilife Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Shandong Weigao Group Medical Polymer Company Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Ningbo David Medical Device Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →B. Braun VetCare
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,323M by 2033 · 7.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Insulin Syringes with Fixed Needle56.9
- Insulin Syringes with Detachable Needle10.9
- Prefilled Insulin Syringes10.5
- Disposable Insulin Syringes21.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$986.0M → $1,870M · 8.3%
Europe$687.2M → $1,305M · 8.4%
Asia Pacific$627.4M → $1,106M · 7.3%
Latin America$388.4M → $686.0M · 7.4%
Middle East and Africa$298.8M → $525.2M · 7.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.442026
7.452027
7.452028
7.462029
7.492030
7.492031
7.502032
7.532033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Becton22.0
- Dickinson and Company (BD)17.7
- Terumo Corporation10.2
- Nipro Corporation10.2
- Eli Lilly and Company6.9
- B. Braun Melsungen AG5.1
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type22.8%
Needle Gauge12.9%
Needle Length38.5%
End User12.5%
Packaging Type13.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.0
- Europe23.8
- Asia Pacific20.1
- Latin America12.5
- Middle East and Africa9.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Becton | 90 | 80 | 97 | 86 | 80 | 98 | 89 |
| Dickinson and Company (BD) | 76 | 92 | 91 | 78 | 78 | 93 | 85 |
| Terumo Corporation | 71 | 88 | 78 | 63 | 81 | 80 | 77 |
| Nipro Corporation | 57 | 75 | 64 | 75 | 67 | 66 | 67 |
| Eli Lilly and Company | 63 | 69 | 60 | 73 | 62 | 77 | 67 |
| B. Braun Melsungen AG | 57 | 47 | 69 | 67 | 57 | 47 | 57 |
| Ypsomed AG | 52 | 41 | 62 | 45 | 63 | 60 | 54 |
| Owen Mumford Ltd | 39 | 55 | 41 | 40 | 55 | 47 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Becton
- Dickinson and Company (BD)
- Terumo Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Becton | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Dickinson and Company (BD) | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Terumo Corporation | ✓ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Nipro Corporation | − | ✓ | ◐ | ✓ | ◐ | ✓ |
| Eli Lilly and Company | ✓ | ✓ | ◐ | − | ◐ | ◐ |
| B. Braun Melsungen AG | − | − | ✓ | ◐ | ◐ | ◐ |
| Ypsomed AG | ◐ | − | − | ◐ | ◐ | − |
| Owen Mumford Ltd | − | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Becton89
2Dickinson and Company (BD)85
3Terumo Corporation77
4Nipro Corporation67
5Eli Lilly and Company67
6B. Braun Melsungen AG57
7Ypsomed AG54
8Owen Mumford Ltd46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
BectonDickinson and Company (BD)
Challenger3
Strong scale, closing on the leaders.
Terumo CorporationNipro CorporationEli Lilly and Company
Contender1
Focused players with pockets of strength.
B. Braun Melsungen AG
Niche2
Specialists in a single segment or region.
Ypsomed AGOwen Mumford Ltd
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Veterinary Insulin Syringes Market — a $539M beachhead inside a $10.4B market.
Beachhead (SOM)$539Mobtainable near-term
Serviceable (SAM)$3.78Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Insulin Syringes with Fixed Needle
Best fit — highest urgency & budget in Product Type.
Economic buyer81 fit
Insulin Syringes with Detachable Needle
Strong fit — clear ROI and a fast path to value.
End user68 fit
Prefilled Insulin Syringes
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Needle Gauge & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Needle Length
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales48%
Partner / channel25%
Digital / self-serve19%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Veterinary Insulin Syringes Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified22%
Evaluation13%
Closed-won7%
$16.3KCAC
$57KLTV
3.5:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Veterinary Insulin Syringes Market is a resilient opportunity — $2.74B by 2033, compounding at 4.4%.
TAM · 2025$1.93Btoday
TAM · 2033$2.74Bforecast
CAGR4.4%2027–2033
Cumulative$20.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.74BTotal addressable market
SAM$1.15BServiceable available market
SOM$215MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.4% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.74BLarge & growingTAM by 2033 at 4.4% CAGR
$1.15BServiceable nowreachable with today’s model
$215MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.13BBear2.9% CAGR
$2.74BBase4.4% CAGR
$3.50BBull5.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Needle Gauge optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Veterinary Insulin Syringes Market — a $6.43B market by 2033. Plan: grow share from 6.8% to 12.2%.
Market size · 2033$6.43Btotal addressable
Market CAGR10.1%2027–2033
Target share12.2%from 6.8% today
Revenue ambition$784Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.8% | 12.2% | Ahead |
| Revenue | $465M | $784M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 34.7% | 41.5% | On track |
| Customer retention | 89.7% | 92.4% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Needle Gauge capability
A defensible second engine — invest in Needle Gauge to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Needle Gauge
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $109M capacity & capability investment
- Greenlight bolt-on M&A in Needle Gauge
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Veterinary Insulin Syringes Market conversation — a $4.62B market you can size, segment and defend in minutes.
Market size · 2033$4.62Btotal opportunity
Growth7.5%CAGR to 2033
Addressable buyers1,123+accounts in scope
Typical ROI4.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.8×return on cost, year one
< 3 mopayback period
$76K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
BectonDickinson and Company (BD)Terumo CorporationNipro CorporationEli Lilly and CompanyB. Braun Melsungen AGYpsomed AGOwen Mumford Ltd+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Veterinary Insulin Syringes Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Veterinary Insulin Syringes Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Veterinary Insulin Drugs Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportVeterinary Instant Coagulation Analyzer Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportVeterinary Injection Puncture Instrument Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportVeterinary Injection Needles Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportVeterinary Injection Equipment Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportVeterinary Inhalation Anesthesia Machine Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportVeterinary Infusion and Syringe Pumps Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportVeterinary Infectious Disease Diagnosis Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportVeterinary Indicator Blood Analyzer Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportVeterinary Implants Market
Market size, share, segmentation and regional forecast.
$392M market · 2025 base year
View reportVeterinary Immunoassay Analyzer Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportVeterinary Imaging Software Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.